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Fas ligand is a type II transmembrane protein which can PA317/FasL revealed massive infiltration of polymorpho-
induce apoptosis in Fas-expressing cells. Recent reports nuclear neutrophils and mononuclear cells. A specific
indicate that expression of FasL in transplanted cells may immune protective effect was observed in animals primed
cause graft rejection and, on the other hand, tumor cells with a mixture of BNL or CT26 and PA317/FasL cells.
may lose their tumorigenicity when they are engineered to Rechallenge with tumor cells 14 or 100 days after priming
express FasL. These effects could be related to recruit- resulted in protection of 100 or 50% of animals, respect-
ment of neutrophils by FasL with activation of their cyto- ively. This protective effect was due to CD8+ cells since
toxic machinery. In this study we investigated the antitumor depletion of CD8+ led to tumor formation. In addition, treat-
effect of allogenic fibroblasts engineered to express FasL. ment of pre-established BNL tumors with a subcutaneous
Fibroblasts engineered to express FasL (PA317/FasL) did injection of BNL and PA317/FasL cell mixture at a distant
not exert toxic effects on transformed liver cell line (BNL) site caused significant inhibition of tumor growth. These
or colon cancer cell line (CT26) in vitro, but they could data demonstrate that allogenic cells engineered with FasL
abrogate their tumorigenicity in vivo. Histological examin- are able to abolish tumor growth and induce specific pro-
ation of the site of implantation of BNL cells mixed with tective immunity when they are mixed with neoplastic cells.
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Introduction
Fas ligand (FasL, CD95L, APO-1L) is a type II transmem-
brane protein of the tumor necrosis factor family that
induces apoptosis in Fas-positive cells.1–3 It is predomi-
nantly expressed in activated T cells and it is one of the
effector molecules for cytotoxic T lymphocyte (CTL) and
NK cell-induced apoptosis.4–6 Mice and humans, with a
defect in Fas expression or function demonstrate a pro-
found lymphoaccumulative disorder together with age-
associated autoimmune phenomena.7–9 Mutation of FasL
gene in mice resulted in similar phenotype (gld-gen-
eralized lymphoproliferative disease).10 This suggests
that the Fas/FasL system plays an important role in the
maintenance of immune homeostasis.11,12
Sertoli cells in the testis and epithelial cells in the
anterior chamber of the eye also express FasL.13–15 The
presence of FasL confers immunological privilege to
these cells and allo- or xenografts transplanted into these
sites are not rejected since FasL expressed by Sertoli cells
and epithelial cells of the anterior chamber of the eye
induce death of infiltrating T cells expressing high levels
of Fas.15 Lau and co-workers16 reported that syngenic
myoblasts engineered to express FasL could delay rejec-
tion of pancreatic islet allografts when transplanted
under the kidney capsule. Recently, expression of FasL
was found on some tumor cells such as melanoma, colon
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cancer cells or hepatocellular carcinoma cells and these
FasL-expressing tumor cells were capable of inducing
apoptosis of lymphocytes, suggesting that this might be
an additional mechanism for malignant cells to escape
immunosurveillance.17–20
On the other hand, it was shown that the presence of
FasL can involve destruction of FasL-bearing cells. First,
Seino et al21 showed that introduction of FasL cDNA into
murine tumor cells did not affect growth in vitro but
caused rejection in vivo. Further, Kang et al22 reported that
transplantation of islets of Langerhans infected with an
adenoviral vector containing FasL into allogenic diabetic
hosts underwent accelerated rejection. Transgenic
expression of CD95 ligand on islet b cells induced a gran-
ulocytic infiltration but did not confer immune privilege
upon islet allografts.23 The authors demonstrated that this
type of rejection was T cell and B cell independent and
was mediated mainly by neutrophils, which involved
local inflammation with further destruction of neighbor-
ing tissues. Until now it has not been known why the
presence of FasL on the surface of cells can confer a state
of immune privilege in some settings while in others it
may precipitate inflammation and cell destruction.24,25
The current study was undertaken to analyze whether
allogenic fibroblasts engineered to express FasL could
abrogate tumorigenicity and induce specific immune
response to tumor antigens in a murine animal model.
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Figure 1 Stable transfectants of fibroblast cell line PA317 were obtained by transfection of the cells with either pCl/FasL or control plasmid pCl and
selection in geneticin-containing medium for 2 weeks. (a) RT-PCR using FasL-specific primers of one colony transfected with pCl/FasL expressing high
level of FasL (PA317/FasL) and one colony transfected with control plasmid pCl which did not express FasL (PA317/Contr). 502 bp of FasL fragment
was only seen in PA317/FasL cells after PCR product was run at 1.5% of agarose gel. (b) The two cell colonies PA317/FasL and PA317/Contr exhibit
similar growth rate as estimated by incorporation of 3H-TdR at different cell densities. Each bar represents mean – s.d. of triplicate determinations.
Results
Stable transfectants of fibroblasts expressing functional
FasL
Stable transfectants of fibroblasts were produced by
transfection of PA317 cells with pCl/FasL or pClneo.
Transfected cells were selected in geneticin-containing
medium and 10 colonies from both transfections were
obtained for screening of FasL expression. Among these
colonies, we selected one colony from pCl/FasL transfec-
tion which expressed a high level of FasL (PA317/FasL)
and one colony from pClneo transfection (lacking FasL
expression) was taken as a control (PA317/Contr) (see
Figure 1a). As shown in Figure 1b growth rate (as esti-
mated by incorporation of 3H-TdR) was similar for
PA317/FasL and PA317/Contr at different densities of
cells.
To assess the function of FasL in transfected cells, we
incubated PA317/FasL or PA317/Contr with YAC-1
cells. These cells are Fas positive and have been used in
other studies as target cells for Fas/FasL interaction.16 As
shown in Figure 2b, PA317/FasL killed YAC-1 cells in a
dose-dependent manner. We observed 31.2, 54.1, 58.9 and
69.3% YAC-1 cell death when effector cells were cocul-
tured with target cells at effector/target ratios of 0.2:1,
0.6:1, 2:1 and 6:1, respectively. In contrast, PA317/Contr
Figure 2 Induction of apoptosis in Fas+ YAC-1 cells by incubation with PA317/FasL. (a) Apoptotic pattern of DNA fragmentation when YAC-1 cells
were cocultured with PA317/FasL cells ; no fragmentation of DNA was observed when YAC-1 cells were incubated alone (YAC-1) or with PA317/Contr.
M indicates molecular weight markers (b) JAM assay for detection of YAC-1 cell death when YAC-1 cells (5 · 103) were co-incubated with PA317/FasL
or Pa317/Contr cells; figures in abscissa indicate the number of effector cells. (c) JAM assay for detection of YAC-1 cell death when they were incubated
with supernatant from PA317/FasL or PA317/Contr cells. Each point represents mean – s.d. of triplicate determinations.
did not induce apoptosis at any effector/target ratio
tested. We also investigated whether supernatants from
PA317/FasL or PA317/Contr cells caused toxicity on
YAC-1 cells. Figure 2c shows that 35, 25 and 20% of cell
death occurred when YAC-1 cells were cultured with
supernatants from PA317/FasL at 1:1, 1:5 and 1:10
dilution, respectively, while no toxic effect on YAC-1 cells
was found when using supernatant from PA317/Contr
cells. Typical apoptotic DNA ladder was seen when
YAC-1 cells were co-incubated with PA317/FasL cells,
but not with PA317/Contr cells (Figure 2a). These data
indicate that PA317/FasL cells express functional FasL
capable of inducing apoptosis in Fas-expressing cells.
In vitro interaction between BNL, CT26 and PA317/FasL
or PA317/Contr cells
Using RT-PCR assay with specific primers derived from
mouse Fas cDNA sequence we could demonstrate that
both transformed liver cell line BNL cells and colon can-
cer CT26 cells did not express Fas. In addition, we
observed that co-incubation of BNL or CT26 cells with
either PA317/FasL or PA317/Contr did not affect the
rate of 3H-TdR incorporation into tumor cells, indicating
that there is no direct interaction between Fas ligand on
the surface of PA317/FasL and BNL or CT26 cells (data
not shown).
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Figure 3 Tumorigenicity of BNL tumor cells in vivo when they were mixed with PA317/FasL cells. BNL cells (5 · 106) alone, a mixture of BNL cells
(5 · 106) and PA317/FasL cells (5 · 106) or PA317/Contr cells (5 · 106) were injected into Balb/c mice subcutaneously. (a) Tumor growth rate and (b)
survival of animals receiving subcutaneous injection of BNL cells, a mixture of BNL+PA317/FasL cells or BNL+PA317/Contr cells at a ratio of 1:1.
It can be observed that PA317/FasL cells abrogate the tumorigenicity of BNL cells, whereas PA317/Contr cells do not influence the rate of tumor growth.
Effect of PA317/FasL cells on tumorigenicity of BNL and
CT26 cells
As shown in Figure 3, PA317/FasL cells mixed at a ratio
of 1:1 with BNL cells totally abrogated the tumorigenicity
of neoplastic cells in such a way that no tumor appeared
in all 12 inoculated animals. In contrast, in the group of
animals given a mixture 1:1 of PA317/Contr and BNL
tumors developed in all eight injected mice. The growing
rate of tumors and animal survival were similar in mice
receiving PA317/Contr+BNL or BNL alone. In animals
given BNL cells mixed with PA317/FasL at a ratio of 2:1,
10:1 and 100:1 tumors appeared in one, four and five of
five mice in each group, respectively (Table 1). In these
animals the incidence of tumors as well as tumor growth
rate increased as the proportion of PA317/FasL cells
decreased (data not shown).
In a separate set of experiments we observed that, simi-
larly to what was found with BNL cells, only one of eight
animals developed a tumor when they received CT26
cells mixed with PA317/FasL at a 1:1 ratio. However, all
eight animals developed tumors when they were given
CT26 cells mixed with PA317/Contr cells at same ratio
(Table 1).
In order to identify the effector cells involved in the
Table 1 Effect of PA317/FasL on tumorigenicity of BNL and
CT26 cells
PA317/FasL BNL Tumor incidence
5 · 106 5 · 106 0/12
2.5 · 106 5 · 106 1/5
5 · 105 5 · 106 4/5
5 · 104 5 · 106 5/5
PA317/Contr
5 · 106 5 · 106 8/8
PA317/FasL CT26
5 · 105 5 · 105 1/8
PA317/Contr
5 · 105 5 · 105 8/8
BNL and CT26 cells were mixed with various proportions of
PA317/FasL or PA317/Contr cells. Cell mixture was injected
s.c. into mice and tumor development was observed.
eradication of the tumor cells, we performed histological
examination of the inoculation site of BNL cells mixed
with either PA317/FasL or PA317/Contr. In mice receiv-
ing a BNL and PA317/FasL cell mixture, a marked
inflammatory response with predominance of infiltrating
neutrophils and mononuclear cells was observed on day
1 (Figure 4a). Among inflammatory cells, cell debris was
seen and BNL cells could not be clearly observed. In ani-
mals given BNL cells mixed with PA317/Contr cells,
BNL cells were clearly identified surrounded by a margin
of slight inflammation, with a few neutrophils and mono-
nuclear cells (Figure 4d). On day 4, a massive infiltration
of polymorphonuclear neutrophils and some mono-
nuclear cells with a remarkable absence of BNL cells was
observed at the site of injection of BNL cells with
PA317/FasL (Figure 4b and c). In contrast, on day 4 obvi-
ous tumor growth with a rim of inflammatory reaction
was noted in the group which received BNL cells
together with PA317/Contr (Figure 4e). On day 7 no
tumoral tissue at the site of tumor implantation was seen
in animals injected with BNL cells mixed with
PA317/FasL, whereas a solid nodule of tumoral cells was
present in the group which received BNL plus
PA317/Contr (Figure 4f).
Induction of protective immunity against tumor cells
To study the protective antitumoral immunity induced
by PA317/FasL, animals previously immunized with
BNL and PA317/FasL or PA317/Contr cells at a ratio 1:1,
were rechallenged on the opposite flank with 5 · 106 or
5 · 107 BNL cells or 5 · 105 CT26 cells on day 14 (short-
term protection) or with 5 · 106 BNL cells on day 100
(long-term protection). None of the animals immunized
with PA317/FasL+BNL and rechallenged with 5 · 106
and 5 · 107 BNL on day 14 (n = 8 per group) developed
tumor growth. In contrast, rechallenge with CT26 cells of
four mice immunized with BNL and PA317/FasL
resulted in tumor formation in all cases. In animals
treated with BNL and PA317/Contr cells, contralateral
injection of BNL cells on day 14 led to tumor develop-
ment in all cases (n = 8) (Table 2). In studies aimed at ana-
lyzing long-term protection, we found that 50% of mice
immunized with BNL and PA317/FasL still exhibited
protection against rechallenge with BNL cells 100 days
after immunization (Table 2).
A specific antitumoral protective effect was also
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Figure 4 Histological examination of the tumor implantation sites. Inflammatory response with predominance of polymorphonuclear neutrophils (thick
short black arrows) and mononuclear cells (thin black arrows) in the infiltrate was observed in mice injected with BNL mixed with PA317/FasL cells
on day 1 after inoculation. Among inflammatory cells cellular debris was seen (white arrows) (a). Massive infiltration of polymorphonuclear neutrophils
and mononuclear cells was present at the site of injection of BNL cells mixed with PA317/FasL at day 4 (b). High magnification field showing polymorpho-
nuclear neutrophils on day 4 in mice injected with BNL plus PA317/FasL (c). A cluster of BNL cells (below black stars) is surrounded by a rim of
mild inflammatory reaction with a few neutrophils and mononuclear cells in animals inoculated with BNL cells mixed with PA317/Contr cells at day
1 after inoculation of the cell mixture (d). Formation of a small tumor nodule (below black stars) with mild peripheral inflammatory response was noted
on day 4 in the group given BNL cells with PA317/Contr (e). A solid tumor nodule was observed on day 7 in the group which received BNL and
PA317/Contr (f). Paraffin sections were stained with hematoxilin and eosin. Magnification a, b, d, e · 400, c · 1000, f · 100.
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Table 2 Tumor protective immunity induced by PA317/FasL
Priming Tumor incidence following rechallenge
Day 14 Day 100
BNL CT26 BNL
BNL+PA317/FasL 5 · 106 0/8 5 · 105 4/4 5 · 106 2/4
5 · 107 0/8 ND ND
BNL+PA317/Contr 5 · 106 8/8 ND ND
CT26+PA317/FasL 5 · 106 4/4 5 · 105 1/8 ND
CT26+PA317/Contr ND 5 · 105 4/4 ND
ND, not done.
observed in mice immunized with CT26 and PA317/FasL
cells, as a tumor appeared in only one of eight animals
when they were rechallenged with CT26 cells on day 14
after immunization, while all four animals immunized
with CT26 and PA317/FasL developed tumors when
they were rechallenged with BNL cells (Table 2). All mice
treated with CT26 plus PA317/Contr developed tumors
after rechallenge with CT26 cells (n = 4).
Administration of monoclonal antibodies anti-CD4+
and anti-CD8+ resulted in a significant decrease of circul-
ating CD4+ and CD8+ lymphocytes (93.4 and 85.2%
reduction, respectively). Depletion of CD8+ lymphocytes
was associated with appearance of tumors in all rechal-
lenged animals, whereas in animals given monoclonal
antibodies anti-CD4+ no tumor formation was observed
(Table 3).
In vivo treatment of established tumor with PA317/FasL
In order to know whether antitumoral immunity induced
by PA317/FasL could eliminate established BNL tumors,
we treated established s.c. tumor (0.5 cm in diameter) by
intratumor injection of PA317/FasL cells or by injection
of a mixture of BNL and PA317/FasL cells at a distal site.
Figure 5a shows that intratumor injection of 5 · 106 of
PA317/FasL to previously established BNL tumors did
not affect the growth of the tumors as compared with
tumors injected with 5 · 106 PA317/Contr. In addition,
we observed no differences in survival of tumor-bearing
mice treated with intratumoral injection of either
PA317/FasL or PA317/Contr (Figure 5b).
Injection of the mixture of PA317/FasL and BNL
(5 · 106 and 5 · 106) cells to animals with previously
established BNL tumors (0.5 cm in diameter) in the con-
Table 3 Involvement of lymphocyte subtypes in tumor protec-
tive immunity induced by PA317/FasL
Priming Antibody Rechallenging Tumor
treatment incidence
BNL+ Anti-CD8 BNL 3/3
PA317/FasL Anti-CD4 BNL 0/3
Animals were primed at day - 14 with a mixture of
BNL+PA317/FasL and rechallenged with BNL cells at day 0.
Anti-CD8+ or anti-CD4+ was given i.p. at days - 3, - 2, - 1 and
then every week for 50 days after challenge.
tralateral flank of the body resulted in significant inhi-
bition of tumor growth, as compared with animals
injected with a mixture of PA317/Contr and BNL cells
(Figure 6a). The survival of mice with established tumors
treated with a mixture of PA317/FasL and BNL cells was
also longer (P , 0.01) than that of animals treated with
a mixture of PA317/Contr and BNL cells (Figure 6b).
Discussion
Many discrepancies exist as to whether expression of
FasL provides immune privilege or destruction of trans-
planted cells. The mechanisms that lead to one outcome
or to the other are unknown. In some settings FasL
expression leads to apoptosis of infiltrating lymphocytes
resulting in immune tolerance. Thus, Sertoli cells, epi-
thelial cells of the anterior chamber of the eye and some
types of tumor cells, such as melanoma and colon cancer
cells which express FasL, as well as myoblasts engineered
to produce FasL can create an immunoprivileged
environment.13–18 Allogenic CT26 colon carcinoma cells
expressing mouse FasL markedly reduced allogenic cyto-
toxic T lymphocytes and completely inhibited generation
of alloantibodies of both IgM and IgG subclasses.26 In
contrast with these experimental findings, the presence
of FasL on the surface of allogenic pancreatic islets failed
to protect these islets from allogenic rejection and this
reaction was found to involve the formation of a granulo-
cytic infiltrate.22 Introduction of human or mouse FasL
cDNA into murine tumor cells did not affect tumor
growth in vitro but caused rejection of the tumor by infil-
trating neutrophils with subsequent induction of tumor-
specific protective immunity.21 More recent data indicate
that adenovirus-mediated gene transfer of mouse FasL
induced tumor regression in animal models implanted
with Fas-positive and -negative tumor cells.27
In the light of the above data we decided to study
whether allogenic fibroblasts engineered to express FasL
are able to abolish tumorigenicity and induce tumor-
specific protective immunity. We decided to transduce
allogenic fibroblasts stably instead of syngenic cells
because transduction with FasL of syngenic cells entails
the risk of inducing a state of immunoprivilege.16 Human
FasL gene was chosen because of its ability to be func-
tional in the soluble form, which could potentiate local
inflammatory response, whereas mouse FasL loses its
activity when it is cleaved from the membrane.28 Further-
more, recombinant soluble human FasL is directly chem-
otactic for mouse neutrophils in vitro. From the practical
point of view, allogenic fibroblasts with functional FasL
seem to be more useful when thinking in terms of poten-
tial applications for treatment of tumors in humans, as
allogenic fibroblasts can be easily prepared in large quan-
tities. These cells can be mixed with irradiated tumor cells
obtained from the patient and inoculated to induce a spe-
cific antitumoral immunity. When thinking in terms of
practical applications, our strategy offers advantages in
respect of the use of adenoviral vectors expressing Fas
ligand, which can induce severe liver toxicity since hepa-
tocytes express Fas constitutively29 and also in respect of
procedures based on direct transduction of tumor cells
with Fas ligand since it is difficult to culture tumor cells
from specific patients.
Our results show that fibroblasts engineered to express
FasL and their supernatant were able to induce apoptosis
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Figure 5 Tumor growth rate and survival of animals with pre-established BNL tumors after intratumoral injection of PA317/FasL or PA317/Contr
cells. Tumors were established by injection of 5 · 106 BNL cells subcutaneously. When tumors were 0.5 cm in diameter, they were treated by intratumor
injection of either 5 · 106 PA317/FasL (n = 5) or PA317/Contr (n = 5) cells. After treatment both the size of the tumors and animal survival were
documented. (a) Tumor growth rate and (b) survival of animals after treatment. No significant differences in tumor growth or survival rates were
observed among mice which received intratumoral injection of PA317/FasL or PA317/Contr cells.
Figure 6 Tumor growth rate and survival of animals with pre-established BNL tumors after contralateral injection of BNL+PA317/FasL or BNL+
PA317/Contr. Tumors were established by injection of BNL cells at 5 · 106 s.c. When tumors were 0.5 cm in diameter, animals were treated by s.c.
injection in the opposite flank with a mixture of 5 · 106 BNL cells with either 5 · 106 of PA317/FasL (n = 5) or PA317/Contr (n = 5) cells. (a) Tumor
growth rate after treatment. Significant inhibition of tumor growth rate was noted in animals subjected to contralateral vaccination with
BNL+PA317/FasL (5 · 106 + 5 · 106) as compared with BNL+PA317/Contr (5 · 106 + 5 · 106). *P , 0.05 (ANOVA test). (b) Survival of animals after
treatment. Significant prolongation of survival was found in animals treated by contralateral vaccination with BNL+PA317/FasL as compared with
BNL+PA317/Contr. P , 0.01 (log rank test).
of Fas-bearing YAC-1 cells. Although PA317/FasL did
not induce toxic effects on BNL or CT26 tumor cells in
vitro, these tumor cells lose their tumorigenicity when
they are implanted into syngenic mice together with
PA317/FasL cells. This observation suggests that
PA317/FasL cells trigger in vivo mechanisms responsible
for tumor suppression. It has been shown that some cyto-
kines such as tumor necrosis factor (TNF), even if they
have no direct action on the target tumor cells in vitro,
can induce antitumor reaction in vivo by potentiating
nonspecific and/or specific host responses against
tumors.30,31 In our study, histologic examination of the
site of implantation revealed the presence of a dense
infiltration of neutrophils and mononuclear cells with
disappearance of tumor cells in animals which received
the mixture of tumor cells and PA317/FasL. In contrast,
mice treated with BNL cells mixed with PA317/Contr
exhibited progressive growth of neoplastic cells with for-
mation of a tumor nodule surrounded by only a mild
inflammatory reaction. This observation, which is similar
to observations in previous reports using FasL-expressing
tumor cells,21 suggests that activation of neutrophils is
a basic mechanism involved in tumor elimination in the
system utilized in the present work.
Importantly, we observed that no tumor occurred after
contralateral rechallenge with BNL cells in animals
treated with BNL and PA317/FasL 14 days before. In
contrast neoplastic growth developed in the same group
of animals after rechallenge with a tumor cell line differ-
ent from that used for immunization. These data point
to a specific antitumoral immune response induced by
treatment with a mixture of neoplastic cells and
PA317/FasL cells. One hundred days after priming with
a BNL and PA 317/FasL cell mixture 50% of animals still
manifested protection. This effect appears to be due to
the induction cytotoxic T cells since depletion of CD8+ T
cells abrogated the protection against tumor formation.
Our unpublished data and reports in the literature32 indi-
cate that both BNL and CT26 are poorly immunogenic
and express low levels of MHC class I antigens and no
class II molecules. Thus, in accordance with previous
studies,21,27 our findings support the idea that immunity
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the immunogenicity of the malignant cells.
In our study no antineoplastic effect was observed by
injecting PA317/FasL intratumorally. Different reasons
might account for this lack of antitumoral effect: first, it
may be possible that the viability of allogenic cells
injected into the solid tumor nodule might not be good
enough to cause biological effects; and second, the
immunosuppressive microenvironment within an estab-
lished tumor33 might prevent neutrophil recruitment and
the induction of an effective antitumoral immunity.
Interestingly, however, contralateral vaccination of ani-
mals with previously established BNL tumors with a
mixture of BNL cells and PA317/FasL resulted in
decreased tumor growth rate and in prolongation of ani-
mal survival, as compared with animals given BNL and
PA317/Contr. These results indicate that treatment of
animals with a mixture of BNL and PA317/FasL cells
was able to induce immune responses which can not only
eliminate tumor cells after rechallenge but also signifi-
cantly inhibit the growth of pre-established tumors. This
finding has important implications for the delineation of
antitumoral strategies in humans aimed at preventing
recurrence after surgical resection of neoplasms or at eli-
minating residual cancer cells after surgical removal of
main, large tumors. These aims could be accomplished
by vaccination of the patient after surgery using allogenic
fibroblasts engineered to express FasL and irradiated
tumor cells obtained at surgery from the same patient.
In summary, our data demonstrate that allogenic cells
engineered with FasL are able to abrogate tumorigenicity
of tumor cells in vivo by recruiting inflammatory cells.
Allogenic fibroblasts expressing FasL are useful for anti-
tumoral vaccination when administered in mixtures with
syngenic tumor cells. This procedure protects against
rechallenge with neoplastic cells and inhibits growth of
established tumors by eliciting a specific antitumor
immune response. These data suggest that local
expression of FasL can be used as a tool for immunother-
apy of cancer.
Materials and methods
Animals, cell culture and reagents
Six- to eight-week-old Balb/c female mice were used in
the study. They were purchased from Charles River
(Barcelona, Spain). During the experimental period ani-
mals were housed under standard conditions. Methyl-
cholanthrene epoxide-transformed mouse liver cell line
BNL 1ME A.7R.1 (BNL) from Balb/c mouse, YAC-1
mouse lymphoma cell line and PA317 mouse fibroblast
cells from Swiss mouse were obtained from American
Type Cell Collection (ATCC, Rockville, MD, USA). Colon
cancer (CT26) cell line from Balb/c mouse was a kind
gift from Dr K Brand, Max-Planck-Institut fur Biochemie
(Germany). The cell lines were cultured at 37 ° C, 5% CO2
in DMEM (BNL, PA317) or RPMI 1640 (CT26, YAC-1)
medium supplemented with 10% fetal calf serum, 2 mm
l-glutamine and penicillin/streptomycin. All media and
supplements were from Biological Industries (Kibbutz
Beit Haemek, Israel) and BioWhittaker (Vervier,
Belgium).
Plasmid construction
The human Fas ligand (FasL) cDNA was released from
pBX-hFL1 plasmid1 (a kind gift from S Nagata) by XbaI
cutting and was cloned into the XbaI site of pCl/neo
eukaryotic expression vector plasmid (obtained from Pro-
mega, Madison, MI, USA). The obtained plasmid
included FasL gene under control of the CMV promoter
together with the linked dominant biochemical selection
marker gene neomycin, a geneticin-resistance gene
driven by simian virus 40 (SV40) promoter, allowing the
selection of transfected cells in geneticin-containing
medium. The orientation of FasL insert relative to
promoter was confirmed by enzyme digestion.
Stable transfection
A newly created plasmid (pCl/FasL) or an empty plas-
mid (pCl/neo) were transfected into PA317 fibroblast cell
line using calcium phosphate transfection method.
Briefly, the 1 · 105 PA317 cells were seeded per well of
six-well plate. On the next day, cells were transfected
with 10 mg of plasmid DNA for 16 h. Two days after
transfection, cells were cultured in geneticin (G418)-con-
taining medium (GibcoBRL, Barcelona, Spain) at a con-
centration of 800 mg/ml for 2 weeks. Approximately 10–
15 colonies from each transfection were picked up for
screening of FasL expression. One colony from pCl/FasL
transfection that expressed high levels of FasL and
another from pCl/neo transfection that did not express
FasL were chosen for further studies and were desig-
nated as PA317/FasL and PA317/Contr.
RNA isolation and RT-PCR
To identify clones with stable expression of FasL, total
RNA was isolated from all colonies using commercial kit
Ultraspec RNA (Biotex, Houston, TX, USA). For RT-PCR,
cDNA was synthesized from 1 mg of total RNA in 10 ml
of volume using M-MuLV reverse transcriptase. PCR
amplification was performed with 4.8 ml cDNA, 100 pmol
each of oligonucleotide primer, 200 mm dNTP, 3 mm
MgCl2, and 2.5 units Taq polymerase in PCR buffer
(Biotaq; Ecogen, Barcelona, Spain) in a total volume of
50 ml for 30 cycles. Each cycle included denaturation at
94 ° C for 1 min, annealing at 60 ° C for 1 min, and primer
extension at 72 ° C for 1 min. The sense and antisense PCR
primers for human FasL gene used were
CAGCTCTTCCACCTACAGAAGG (5 ¢ to 3 ¢ , nt 371–392
corresponding to published sequence from GenBank
accession no. U11821) and CAAAATTGACCAGAGA-
GAGCTC (5 ¢ to 3 ¢ , nt 872–851). 502 bp of FasL fragment
was obtained after PCR amplification. As a control we
used amplification of the b-actin gene.34 To analyze Fas
expression in BNL and CT26 cells we used 1 mg of total
RNA for reverse transcription, followed by amplification
using mouse Fas primers in above conditions for 30
cycles. The sense and antisense PCR primers for mouse
Fas gene used were GCTGGCTCACAGTTAAGAGT (5 ¢
to 3 ¢ , nt 86–105 corresponding to the published
sequence)35 and CAACCATAGGCGATTTCTGG (5 ¢ to 3 ¢ ,
nt 565–546). 480 bp of Fas fragment was obtained after
PCR amplification.
To measure the growing rate of PA317/FasL and
PA317/Contr, cells were seeded in triplicate in a 96-well
dish at 1 · 103, 5 · 103, 1 · 104 cells per well for 48 h and
then were labeled with 3H-TdR (methyl-3H thymidine;
Amersham Iberica, Madrid, Spain) for 8 h. Finally, cells
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was given as above.
Assessment of DNA fragmentation in target cells
The function of Fas ligand in stably transfected PA317
cells was assessed by quantification of DNA fragmen-
tation of target cells by the JAM test.36 The adherent
PA317/Fasl and PA317/Contr cells were seeded in tripli-
cate into a flat-bottomed 96-well microtiter plate at
1 · 103, 3 · 103, 1 · 104, 3 · 104 cells and were incubated
in complete DMEM medium at 37 ° C for 24 h. Target Fas-
positive YAC-1 cells were labeled by prior incubation
with 10 mCi of 3H-TdR in complete RPMI 1640 medium
at 37 ° C for 16 h. Labeled target cells were washed and
5 · 103 of cells were added to the seeded effector cells in
a final volume of 100 ml of complete RPMI 1640 medium.
After coculture at 37 ° C for 8 h, the cells were removed
from the wells by pipetting up and down five times and
were collected by filtration on to glass fiber filters using
a 96-well filtration unit. The cells were hypotonically
lysed, and fragmented DNA was washed through the fil-
ter four times with 0.25 ml water. The radioactivity of
intact chromosomal DNA retained on each filter was
measured by liquid scintillation counting. Specific cell
killing was calculated using the following equation:
% specific killing = (S - E/S) · 100
where E (experimental) is c.p.m. of retained DNA in the
presence of effector cells and S (spontaneous) is c.p.m. of
retained DNA in the absence of effector cells. Clones of
PA317/FasL with the most pronounced activity and one
of PA317/Contr were selected for further studies. To
study the activity of the soluble form of Fas ligand, the
supernatants from 3-day confluent cultures of
PA317/Fasl and PA317/Contr were harvested and fil-
tered through 0.45-mm pore filters and stored at 4 ° C until
the experiment. Preparation of target YAC-1 cells was the
same as above. On the day of the study, three dilutions of
supernatant were prepared (1:1, 1:5 and 1:10) and 5 · 103
target YAC-1 cells were added to a final volume of 100 ml
in complete RPMI 1640 medium on a 96-well dish. Then,
cells were incubated for 8 h and harvested, c.p.m.
measurement and calculation were made as stated above.
For analysis of DNA fragmentation by electrophoresis,
1 · 106 YAC-1 cells were cocultured in complete RPMI
1640 medium with a confluent monolayer of previously
washed PA317/Fasl or PA317/Contr in 10-cm plates for
8 h. Then, floating YAC-1 cells were harvested, washed
once and resuspended in lysing buffer (10 mm Tris/HCl
pH 8.0; 10 mm EDTA; 0.5% Triton X). Tubes were then
transferred to ice and the cells were lysed for 5 min. After
centrifugation at 13 000 g, the supernatant was treated
with 100 mg/ml RNAse (Boehringer Mannheim,
Penzberg, Germany) for 2 h at 37 ° C. Then, SDS and pro-
teinase K (Sigma, St Louis, MO, USA) were added to a
final concentration of 0.5% and 200 mg/ml, respectively.
The extracts were left for 2 h at 50 ° C, and subsequently
supernatants were carefully collected. The low molecular
weight DNA was extracted twice in phenol and
phenol/chloroform, and ethanol precipitated. Finally, the
DNA was resuspended in TE buffer and loaded on to
1.5% agarose gel.
In vitro interaction between BNL, CT26 and PA317/FasL
or PA317/Contr cells
BNL or CT26 cells were labeled with 3H-TdR and then
were trypsinized, washed three times, and mixed with
either PA317/FasL or PA317/Contr. The mixed cells (104
of tumor cells and 104 PA317/FasL or PA317/Contr)
were seeded into 96-well plates in triplicate and incu-
bated for 8 h. Finally, cells were harvested and measure-
ment of radioactivity and calculations were performed as
stated above.
In vivo evaluation of tumor growth
BNL cells as well as CT26 cells were mixed at a ratio of
1:1 with either PA317/FasL (n = 12 for BNL and n = 8 for
CT26) or PA317/Contr (n = 8 for both BNL and CT26),
and the mixture inoculated s.c. into one flank of Balb/c
mouse. The number of injected cells was 5 · 106 for BNL
and 5 · 105 for CT26 cells. In additional experiments
5 · 106 BNL cells were mixed with PA317/FasL or
PA317/Contr cells at the ratios 1:1, 1:2, 1:10 and 1:100
(n = 5, in all cases).
To study protective immunity, Balb/c mice were
inoculated with BNL cells or with CT26 cells mixed at a
ratio of 1:1 with either PA317/FasL or PA317/Contr in
one flank of the body, and 14 days later animals were
rechallenged with 5 · 106 (n = 8) or 5 · 107 (n = 8) BNL, or
5 · 105 (n = 4) CT26 in the opposite flank of the body.
Four additional mice were rechallenged with 5 · 106 BNL
cells 100 days after receiving the mixture of BNL cells
with PA317/FasL at a ratio of 1:1.
For treatment of established tumors, mice received
5 · 106 BNL cells. After 30–40 days animals developed
tumors of 0.5 cm in diameter. In some experiments we
injected intratumorally 5 · 106 of PA317/FasL (n = 5) or
PA317/Contr (n = 5) cells and in other experiments ani-
mals were injected s.c. in the opposite flank of the body
with 5 · 106 BNL cells mixed at a ratio of 1:1 with
PA317/FasL (n = 5) or PA317/Contr (n = 5) cells. Tumor
growth was assessed by periodically measuring perpen-
dicular diameters with a caliper. Tumor volume was cal-
culated from the square of the longest diameter (a) multi-
plied by a smaller diameter (b) of the tumor (V = a · b2).
Mice free of tumors 100 days after challenge were classi-
fied as survivors. Animals with tumors that exceeded
1.5 cm in two perpendicular diameters or 2.0 cm in one
were killed for humanitarian reasons.
In vivo depletion of lymphocytes and tumor incidence
L3T4 (CD4+)-specific rat anti-mouse hybridoma GK1–5
and (CD8+)-specific rat anti-mouse hybridoma H35.17.2
were used to obtain anti-CD4+ and anti-CD8+ antibodies.
Ascitic fluid was obtained from nude mice pristane-
primed and injected with 106 hybridoma cells. Antibodies
were prepared by precipitation with ammonium sulphate
and dialyzed against phosphate-buffered saline. The pro-
tein concentration was assessed by measurement of the
OD at 280 nm. Mice, three in each group, were depleted
of CD4+ or CD8+ cells by i.p. injection of 300 mg of anti-
CD4+ or anti-CD8+ antibodies,37 on days - 3, - 2, - 1 and
every 7 days for 50 days, following rechallenge with
5 · 106 BNL cells (this was done on day 0). On day - 14
all animals were primed with the mixture of BNL cells
and PA317/FasL at a ratio of 1:1 in the flank contralateral
to that of the site of rechallenge. The efficiency of the
depletion was assessed by flow cytometry on day 10.
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50 days.
Histological examination
Mice were inoculated subcutaneously with 5 · 106 BNL
cells mixed with PA317/FasL or PA317/Contr cells at a
ratio of 1:1. On days 1, 4 and 7, the inoculated site was
dissected, fixed in 10% neutral-buffered formalin, and
embedded in paraffin. Sections of 5 mm were stained with
hematoxylin and eosin.
Acknowledgements
MD was granted a fellowship from the Fundacio`n
Empresa Universidad de Navarra, RB was granted by
Programa de Formacio`n de Investigadores e Investiga-
cio`n del Gobierno Vasco. We are grateful to S Nagata for
the kind gift of pBX-hFL1 plasmid carrying the human
Fas ligand gene. We also would like to thank P Azul-
guren for her excellent technical assistance. This work has
been funded in part with Gene Therapy Grants from J
Vidal, M Mendez and Dr Cervera.
References
1 Takahashi T et al. Human Fas ligand: gene structure chromo-
somal location and species specificity. Int Immunol 1994; 6:
1567–1574.
2 Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning
and expression of the Fas ligand, a novel member of the tumor
necrosis factor family. Cell 1993; 75: 1169–1178.
3 Nagata S. Fas and Fas ligand: a death factor and its receptor.
Adv Immunol 1994; 57: 129–144.
4 Kagi D et al. Fas and perforin pathway as major mechanisms of
T cell-mediated cytotoxicity. Science 1994; 265: 528–539.
5 Lowin B, Hahne M, Matthman C, Tschopp J. Cytotoxic T cell
cytotoxicity is mediated through perforin and Fas lytic path-
ways. Nature 1994; 370: 650–652.
6 Kondo T et al. Essential roles of the Fas ligand in the develop-
ment of hepatitis. Nature Med 1997; 3: 409–413.
7 Rieux-Lucat F et al. Mutations in Fas associated with human
lymphoproliferation syndrome and autoimmunity. Science 1995;
268: 1347–1349.
8 Fischer GH et al. Dominant interfering Fas gene mutations
impair apoptosis in a human autoimmune lymphoproliferative
syndrome. Cell 1995; 81: 935–946.
9 Matsuzawa A et al. A new allele of the lpr locus, lprcg, that
complements the gld gene in induction of lymphadanopathy in
the mouse. J Exp Med 1990; 171: 519–539.
10 Takahashi T et al. Generalized lymphoproliferative disease in
mice caused by a point mutation in the Fas ligand. Cell 1994;
76: 969–976.
11 Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the
homeostatic regulation of immune responses. Immunol Today
1995; 16: 569–574.
12 Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in
immune privilege. Immunol Today 1997; 18: 240–244.
13 Griffith TS et al. Fas ligand-induced apoptosis as a mechanism
of immune privilege. Science 1995; 270: 1189–1192.
14 Nagata S. Fas ligand and immune evasion. Nature Med 1996; 2:
1306–1307.
15 Bellgrau D, et al. A role for CD95 ligand in preventing graft
rejection. Nature 1995; 377: 630–632.
16 Lau HT, Yu M, Fontana A, Stoeckert ChJ. Prevention of islet
allograft rejection with engineered myoblasts expressing FasL
in mice. Science 1996; 23: 109–112.
17 Hahne M et al. Melanoma cell expression of fas (APO-1/CD95)
ligand: Implications for tumor immune escape. Science 1996; 274:
1363–1366.
18 O’Connel J, O’Sullivan GC, Collins JK, Shanahan F. The Fas
counterattack: Fas mediated T cell killing by colon cancer
expressing Fas ligand. J Exp Med 1996; 84: 1075–1082.
19 Strand S et al. Lymphocyte apoptosis induced by CD96 (APO-
1/Fas) ligand-expressing tumor cells – a mechanism of immune
evasion? Nature Med 1996; 2: 1361–1366.
20 Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in
immune escape – the tumor cell strikes back. J Immunol 1997;
158: 4521–4524.
21 Seino KI, Kayagaki N, Okumura K, Yagita H. Antitumor effect
of locally produced CD95 ligand. Nature Med 1997; 3: 165–170.
22 Kang S-M et al. Fas ligand expression in islets of Langerhans
does not confer immune privilege and instead targets them for
rapid destruction. Nature Med 1997; 3: 738–743.
23 Allison J, Georgiou HM, Strasser A, Vaux D. Transgenic
expression of CD95 ligand on islet b cells induces a granulocytic
infiltration but does not confer immune privilege upon islet allo-
grafts. Proc Natl Acad Sci USA 1997; 94: 3943–3947.
24 Green DR, Ware CF. Fas-ligand: privilege and peril. Proc Natl
Acad Sci USA 1997; 94: 5986–5990.
25 Lau HT, Stoeckert CJ. FasL – too much of a good thing? Nature
Med 1997; 7: 727–728.
26 Arai H, Chan SY, Bishop KD, Nabel GJ. Inhibition of alloanti-
body response by CD95 ligand. Nature Med 1997; 3: 843–848.
27 Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas
ligand induces tumor regression in vivo. Proc Natl Acad Sci USA
1997; 94: 13862–13867.
28 Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365.
29 Zhang HG et al. Application of a Fas ligand encoding a recombi-
nant adenovirus vector for prolongation of transgene
expression. J Virol 1998; 72: 2483–2490.
30 Havell EA, Fiers W, North RJ. The antitumor effect of tumor
necrosis factor (TNF). J Exp Med 1988; 167: 1067–1085.
31 Beutler B, Cerami A. The biology of cachectin/TNF: a primary
mediator of the host response. Ann Rev Immunol 1989; 7: 625–
655.
32 Fearon ER et al. Interleukin-2 production by tumor cells
bypasses T helper function in the generation of an antitumor
response. Cell 1990; 60: 397–403.
33 Wojtowicz-Praga S. Reversal of tumor-induced immunosupres-
sion: a new approach to cancer therapy. J Immunother 1997; 20:
165–177.
34 Qian C et al. The stilbene disulfonic acid DIDS stimulates the
production of TNF-a in human lymphocytes. Bio Biophys Res
Com 1992; 189: 1268–1274.
35 Watanabe-Fukunaga R et al. The cDNA structure, expression,
and chromosomal assignment of the mouse Fas antigen. J Immu-
nol 1992; 148: 1274–1279.
36 Matzinger P. The JAM test. A simple assay for DNA fragmen-
tation and cell death. J Immunol Meth 1991; 145: 185–192.
37 Lasarte JJ, Sarobe P, Prieto J, Borra´s-Cuesta F. In vivo T lympho-
cyte induction may take place via CD8 T helper lymphocytes.
Res Immunol 1995; 146: 35–44.
